以PD-1 为靶点的抗肿瘤药物专利现状分析

PD-1(程序性死亡受体1)是一种重要的免疫抑制分子,其与癌症的治疗密切相关。目前FDA(美国食品药品监督管理局)已经批准了PD-1抑制剂抗体作为癌症治疗药,因此,PD-1具有极高的研究和应用价值。目前在专利领域,全球各大药企均已经开始专利布局,而在中国申请的专利也是日趋增多,对于我国企业来说,把握时机提前布局专利申请,有利于识别竞争对手,抢占市场。本文通过分析以PD-1为靶点的药物专利现状,特别是研究的重点领域,专利申请的国内重点布局等方面,为国内的申请人未来的研发方向和专利布局提供适当的指引。

Analysis on Patents of Anti-tumor Drugs Targeting PD-1

Programmed cell death-1 (PD-1), an important immunosuppressive molecule, was involved in the treatment of cancers and infectious diseases. Humanized antibody against human PD-1 has been approved by Food and Drug Administration (FDA) of the United States as an investigational new drug, and PD-1 could be very valuable for the research and application. Currently, all of the world''s largest pharmaceutical companies have started patent layout in the field of PD-1. Because of the increasing application of the related patent in China, advanced patent layout will benefit the local enterprise to identify competitors and capture the market prior. In this paper, the statues of patents distribution in anti-tumor drugs targeting PD-1, especially applications in the key areas were analyzed, which could direct internal applicants for appropriate research ideas and suitable patent application strategy.